The Filing Desk

Precision Biosciences vs Kymera Therapeutics

Precision Biosciences DTIL · Kymera Therapeutics KYMR · Biotechnology

Kymera Therapeutics reported revenue of $39 million in fiscal 2025, about the same as Precision Biosciences' $34 million in fiscal 2025. Precision Biosciences' revenue fell 50.1% in its latest year, and Kymera Therapeutics' fell 16.7%. Precision Biosciences had an operating margin of -152.2%, against -891.1% at Kymera Therapeutics. Free cash flow was −$66 million at Precision Biosciences and −$234 million at Kymera Therapeutics.

Side by side

Precision BiosciencesKymera Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$34M$39M
Revenue growth−50.1%−16.7%
Revenue growth a year, last 5 years7.1%2.9%
Gross margin—0.0%
Operating margin−152.2%−891.1%
Net margin−133.4%−794.0%
Free cash flow−$66M−$234M
Free cash flow margin−192.4%−597.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count86.3%12.6%
Last close$6.91$119.39
P/E at the last close——
Insider trades, last 12 monthsbought $63,215, sold $412,359bought $172.5 million, sold $461.2 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Precision BiosciencesKymera Therapeutics
Operating margin
Percent of revenue
Precision BiosciencesKymera Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Precision BiosciencesKymera Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Precision Biosciences and Kymera Therapeutics pages.